Synthesis of Fe3O4@MIL-101-OH/Chitosan for adsorption and release of doxorubicin
Iman Najafipour, Nafiseh Emami, Pegah Sadeh, Adonis Amoli, Sareh Mosleh-Shirazi, Ali Mohammad Amani, Hesam Kamyab, Shreeshivadasan Chelliapan, Seyed Reza Kasaee, Ehsan Vafa
Abstract
This study reports the synthesis and characterization of a magnetic composite metal-organic framework, The Fe 3 O 4 @MIL-101-OH/Chitosan nanocomposite was used for the first time to adsorb and release the drug doxorubicin (DOX). The nanocomposite was characterized using scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), Brunauer-Emmett-Teller (BET), X-ray diffraction (XRD), and vibrating sample magnetometry (VSM). The characterization results showed that the synthesized nanocomposite has a crystalline structure and good magnetic properties. Also, this nanocomposite has a high specific surface area (610.36 m 2 /g). In this article, the effect of pH, contact time, and drug concentration on DOX adsorption were investigated, and the results showed that at optimal conditions, pH=8, contact time=90 min, and drug concentration is 350 ppm, the adsorption capacity of MIL-101-OH/Chitosan and Fe 3 O 4 @MIL-101-OH/Chitosan are equal to 185 and 174.3 mg/g. The adsorption data follows pseudo-second-order kinetic and Langmuir isotherm models. The adsorption was physical and reversible. As a result, drug release was checked. The Fe 3 O 4 @MIL-101-OH/Chitosan exhibited a controlled release over the period of 84 hr at pH 5 and reached 80% of the DOX release rate after 60 hours. In conclusion, the Fe 3 O 4 @MIL-101-OH/Chitosan composite has great potential as a drug delivery system as a result of its high adsorption capacity and magnetic properties. This research provides a promising approach for the development of novel drug delivery systems for cancer therapy. • The Fe 3 O 4 @MIL-101-OH/Chitosan exhibited a crystalline structure, high surface area, and magnetic properties. • The results of the adsorption studies followed a Langmuir isotherm and pseudo-second-order model. • The Fe 3 O 4 @MIL-101-OH/Chitosan exhibited a controlled release of doxorubicin over the time and pH dependent manner. • The novel Fe 3 O 4 @MIL-101-OH/Chitosan composite could be applied for the development of drug delivery systems in cancer therapy.